Lupin Financial and Company Overview

India: An ongoing story of sustained outperformance Lupin has grown better than the market ex-in-licensed portfolio across FY23 Leveraging leadership by adding 6 new divisions LUPIN Overall Non-IL 14.3% 11.3% 10.2% #2 rank Respiratory D #3 rank #3 rank Diabetes Care Cardiac 7.6% 7.5% 6.2% 2.8% 1.1% Q1 FY23 Q2 FY23 Q3 FY23 Q4 FY23 Leveraging therapy strength by adding ~1,000 ME in 6 new divisions to reach ~7,000 Total MES¹ and 9,100 total sales force Gaining significant launch momentum with multiple new introductions in the quarter • Cardiac and respiratory are back on growth trajectory Cardiac, GI, Respiratory and Gynaecology registered double- digit growth since H2 FY23 Diabetes is recovering from impact of patent expiries in segment 1 in 2 in 1 in Diabetes Care Cardiac Anti-infective Lupin grew close to par with market at 14.3% in Q4 excluding in-licensed portfolio Launched a total of 16 products with 53 SKUs in FY23 • Poised to launch ~21 products in FY24 Note: 1. As of 31-Mar-23 9

View entire presentation